A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: No pharmacologic therapy has conclusively proved to be effective for the treatment of nonalcoholic steatohepatitis, which is characterized by insulin resistance, steatosis, and necroinflammation with or without centrilobular fibrosis. Pioglitazone is a thiazolidinedione that ameliorates insulin resistance and improves glucose and lipid metabolism in type 2 diabetes mellitus. METHODS: We randomly assigned 55 patients with impaired glucose tolerance or type 2 diabetes and liver biopsy-confirmed nonalcoholic steatohepatitis to 6 months of treatment with a hypocaloric diet (a reduction of 500 kcal per day in relation to the calculated daily intake required to maintain body weight) plus pioglitazone (45 mg daily) or a hypocaloric diet plus placebo. Before and after treatment, we assessed hepatic histologic features, hepatic fat content by means of magnetic resonance spectroscopy, and glucose turnover during an oral glucose tolerance test ([14C]glucose given with the oral glucose load and [3H]glucose given by intravenous infusion). RESULTS: Diet plus pioglitazone, as compared with diet plus placebo, improved glycemic control and glucose tolerance (P<0.001), normalized liver aminotransferase levels as it decreased plasma aspartate aminotransferase levels (by 40% vs. 21%, P=0.04), decreased alanine aminotransferase levels (by 58% vs. 34%, P<0.001), decreased hepatic fat content (by 54% vs. 0%, P<0.001), and increased hepatic insulin sensitivity (by 48% vs. 14%, P=0.008). Administration of pioglitazone, as compared with placebo, was associated with improvement in histologic findings with regard to steatosis (P=0.003), ballooning necrosis (P=0.02), and inflammation (P=0.008). Subjects in the pioglitazone group had a greater reduction in necroinflammation (85% vs. 38%, P=0.001), but the reduction in fibrosis did not differ significantly from that in the placebo group (P=0.08). Fatigue and mild lower-extremity edema developed in one subject who received pioglitazone; no other adverse events were observed. CONCLUSIONS: In this proof-of-concept study, the administration of pioglitazone led to metabolic and histologic improvement in subjects with nonalcoholic steatohepatitis. Larger controlled trials of longer duration are warranted to assess the long-term clinical benefit of pioglitazone. (ClinicalTrials.gov number, NCT00227110 [ClinicalTrials.gov] .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Significant improvements were observed in hepatic steatosis, hepatocellular ballooning, necrosis, and inflammation; however, fibrosis reduction did not reach statistical significance compared with placebo.”
From Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages (2026) · cites this paper as [202]
In the citing paper
“Accruing randomized clinical trial data suggest that pioglitazone, GLP-1 RA, and a dual GIP and GLP-1 RA have potential benefits in terms of decreasing hepatic steatosis and in the resolution of MASH without worsening of fibrosis in individuals with biopsy-proven MASH or those at higher risk of clinically significant liver fibrosis identified with noninvasive tests (146-153).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [146]
In the citing paper
“Treatment with exenatide reduced liver steatosis [109,146,150] and when added to pioglitazone, an oral hypoglycemic and insulin sensitizing drug approved for the treatment of T2D that acts on nuclear peroxisome proliferator activated receptor-gamma (PPAR-γ) [147], potentiated the known action of pioglitazone in reducing hepatic fat [92].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [92]
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652
Matsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621
Self-citationYamauchi, T., Kamon, J., Minokoshi, Y., Ito, Y., Waki, H., Uchida, S., Yamashita, S., Noda, M., Kita, S., Ueki, K., et al. (2002) · Nature Medicine · doi:10.1038/nm788 · Cited by 4,238
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664
Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease
Ratziu, V., Charlotte, F., Heurtier, A., Gombert, S., Giral, P., Bruckert, E., Grimaldi, A., Capron, F., & Poynard, T. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.03.084 · Cited by 2,106
Molecular mediators of hepatic steatosis and liver injury
Browning, J. D., & Horton, J. D. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422422 · Cited by 1,772
Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease
Samuel, V. T., Liu, Z.-X., Qu, X., Elder, B. D., Bilz, S., Befroy, D., Romanelli, A. J., & Shulman, G. I. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313478200 · Cited by 1,322
Xu, A., Wang, Y., Keshaw, H., Xu, L. Y., Lam, K. S. L., & Cooper, G. J. S. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200317797 · Cited by 1,298
Xu, A., Wang, Y., Keshaw, H., Xu, L. Y., Lam, K. S. L., & Cooper, G. J. S. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17797 · Cited by 1,296
Research works printed but not linked: 3
- 10.1111/j.1572-0241.2003.08699.x · doi:10.1111/j.1572-0241.2003.08699.x · Paper page
- 10.1210/jc.87.6.2784 · doi:10.1210/jc.87.6.2784 · Paper page
- 10.1172/JCI22422 · DOI · Paper page
Cited by
Items 801–900 of 1,003
NAFLD: An Emerging Causal Factor for Cardiovascular Disease
Li, M., Wang, H., Zhang, X., Cai, J., & Li, H. (2023) · Physiology · doi:10.1152/physiol.00013.2023 · Cited by 49
Fatty Liver and Liver Transplantation
Koehler, E. M., Watt, K. D. S., & Charlton, M. (2009) · Clinics in Liver Disease · doi:10.1016/j.cld.2009.07.010 · Cited by 37
“A recent report suggested histologic and biochemical improvement in patients with NASH following therapy with a thiazolidinedione (pioglitazone).(41) Unfortunately, although pioglitazone produces histologic and biochemical improvement in patients with NASH, it can be associated with a significant increase in BMI and p…”
BackgroundKanai, S., Ishihara, K., Kawashita, E., Tomoo, T., Nagahira, K., Hayashi, Y., & Akiba, S. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.229906 · Cited by 39
“Although several clinical trials have demonstrated benefits for pioglitazone in patients with NAFLD and NASH (Belfort et al., 2006; Aithal et al., 2008; Sanyal et al., 2010), long-term treatment with pioglitazone is associated with weight gain (Sanyal et al.”
BackgroundKawaguchi, T., Ueno, T., Nogata, Y., Hayakawa, M., Koga, H., & Torimura, T. (2016) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2016.2831 · Cited by 38
“Pioglitazone, an insulin-sensitizing anti-diabetic agent, leads to metabolic and histologic improvement in patients with NASH (9).”
Non-Alcoholic Fatty Liver Disease, an Overview.
Muhammad, A. (2019) · PubMed Central · Cited by 52
Non-alcoholic Fatty Liver Disease and Diabetes Mellitus
Khneizer, G. W., Rizvi, S., & Gawrieh, S. (2020) · Advances in experimental medicine and biology · doi:10.1007/5584_2020_532 · Cited by 44
Mills, E. P., Brown, K. P. D., Smith, J. D., Vang, P. W., & Trotta, K. (2017) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018817741852 · Cited by 41
Self-citationTakihata, M., Nakamura, A., Tajima, K., Inazumi, T., Komatsu, Y., Tamura, H., Yamazaki, S., Kondo, Y., Yamada, M., Kimura, M., et al. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12055 · Cited by 38
“Pioglitazone has been reported to have various effects other than its glucoselowering effect, such as the improvement of arteriosclerosis [18,19], inflammatory markers [20], liver function [21] and renal function [22]; on the other hand, whether sitagliptin has such effects is not evident.”
BackgroundSharma, B. C., Kumar, A., Garg, V., Reddy, R. S. L., Sakhuja, P., & Sarin, S. K. (2012) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2012.10.010 · Cited by 38
“N A LD that increase insulin sensitivity, has shown promising results.(12,13) There has been no trial comparing the beneficial effect of pentoxifylline and pioglitazone in improving the biochemical, metabolic and histological profile in patients with NASH.”
BackgroundResultSaely, C. H., Vonbank, A., Rein, P., Woess, M., Beer, S., Aczél, S., Jankovic, V., Boehnel, C., Risch, L., & Drexel, H. (2008) · Clinica Chimica Acta · doi:10.1016/j.cca.2008.07.024 · Cited by 36
Mulder, P., Morrison, M. C., Verschuren, L., Liang, W., van Bockel, J. H., Kooistra, T., Wielinga, P. Y., & Kleemann, R. (2016) · Scientific Reports · doi:10.1038/srep31542 · Cited by 43
“Clinical trials have shown that treatment with thiazolidinediones can improve liver histology in patients with NASH 33,34 .”
Gu, Y., Sun, L., He, Y., Yang, L., Deng, C., Zhou, R., Kong, T., Zhang, W., Chen, Y., Li, J., et al. (2023) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2023.2172397 · Cited by 36
Gupta, A., Bray, G. A., Greenway, F. L., Martin, C. K., Johnson, W. D., & Smith, S. R. (2009) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2009.05.004 · Cited by 39
“Pio reduced hepatic steatosis in subjects with impaired glucose tolerance and diabetes mellitus (Belfort et al., 2006).”
BackgroundPharmacological management of type 2 diabetes: the potential of incretin‐based therapies
Charbonnel, B. H., & Cariou, B. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01317.x · Cited by 42
“Alternatively, thiazolidinedione (TZD) should be considered in subjects with insulin resistance and/or non-alcoholic fatty liver disease (NAFLD) [11].”
BackgroundManagement of Nonalcoholic Steatohepatitis
Mahady, S. E., & George, J. (2012) · Clinics in Liver Disease · doi:10.1016/j.cld.2012.05.003 · Cited by 41
Lidofsky, S. D. (2008) · Current Diabetes Reports · doi:10.1007/s11892-008-0006-1 · Cited by 41
An endocrine perspective of nonalcoholic fatty liver disease (NAFLD)
Lomonaco, R., Chen, J., & Cusi, K. J. (2011) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018811419157 · Cited by 45
“The first proof-of-concept controlled trial [Belfort et al. 2006] in patients with NASH and either with IGT or T2DM, demonstrated that pioglitazone significantly lowered liver aminotransferases, increased plasma adiponectin levels and improved adipose tissue, liver and muscle insulin sensitivity.”
BackgroundResultSelf-citationNon-alcoholic Fatty Liver Disease: A Review of Anti-diabetic Pharmacologic Therapies
Snyder, H. S., Sakaan, S. A., March, K. L., Siddique, O., Cholankeril, R. T., Cummings, C. D., Gadiparthi, C., Satapathy, S. K., Ahmed, A., & Cholankeril, G. T. (2018) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2017.00050 · Cited by 42
“While the pioglitazone group experienced improvements in inflammation, ballooning necrosis, and steatosis compared to placebo, there was no significant difference in reduction of fibrosis between the groups.(22) The PIVENS trial was a large double-blind, placebo-controlled trial that compared the effects of pioglitazo…”
ResultCho, I.-J., Oh, D.-H., Yoo, J. H., Hwang, Y., Ahn, K. J., Chung, H.-Y., Jeong, S. W., Moon, J.-Y., Lee, S. H., Lim, S., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-88872-7 · Cited by 40
Liver Fibrogenesis in Non-Alcoholic Steatohepatitis
Bian, Z., & Ma, X. (2012) · Frontiers in Physiology · doi:10.3389/fphys.2012.00248 · Cited by 45
“Furthermore, pioglitazone also decreased liver fibrosis in patients with NASH (Gastaldelli et al., 2010; Ratziu et al., 2010); though another study reported pioglitazone could decrease inflammation in liver, but did not affect liver fibrosis (Belfort et al., 2006).”
BackgroundYang, H., Suh, D. H., Kim, D., Jung, E. S., Liu, K., Lee, C. H., & Park, C. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14434 · Cited by 38
“TZDs have provided histological benefit by improving steatosis and inflammation in many clinical trials (Promrat et al., 2004; Belfort et al., 2006; Sanyal et al., 2010; Cusi et al., 2016).”
BackgroundMarchesini, G., Bugianesi, E., Burra, P., Marra, F., Miele, L., Alisi, A., Vajro, P., Masarone, M., Petta, S., Persico, M., et al. (2022) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.04.028 · Cited by 35
Kounatidis, D. C., Vallianou, N. G., Rebelos, E., Kouveletsou, M., Kontrafouri, P., Eleftheriadou, I., Diakoumopoulou, E., Karampela, Ι., Tentolouris, N., & Dalamaga, Μ. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00612-4 · Cited by 48
“Initial evidence of its efficacy arose from a six-month proof-of-concept study involving adults with impaired glucose tolerance or T2DM [97, 98].”
Potential protective effect of Nigella sativa crude oils towards fatty liver in rats
Al‐Okbi, S. Y., Mohamed, D. A., Hamed, T. E.-S., & Edris, A. E. (2013) · European Journal of Lipid Science and Technology · doi:10.1002/ejlt.201200256 · Cited by 40
“In addition, insulin sensitizers have shown efficacy in some human studies [12–14].”
BackgroundPitavastatin inhibits hepatic steatosis and fibrosis in non‐alcoholic steatohepatitis model rats
Miyaki, T., Nojiri, S., Shinkai, N., Kusakabe, A., Matsuura, K., Iio, E., Takahashi, S., Yan, G., Ikeda, K., & Joh, T. (2011) · Hepatology Research · doi:10.1111/j.1872-034x.2010.00769.x · Cited by 38
El-Haleim, E. A. A., Bahgat, A. K., & Saleh, S. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.01.011 · Cited by 39
Toppo, E., Darvin, S. S., Esakkimuthu, S., Nayak, M. K., Balakrishna, K., Kuppusamy, S., Pandikumar, P., Savarimuthu Ignacimuthu, S. J., & Al-Dhabi, N. A. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.08.071 · Cited by 37
Enooku, K., Kondo, M., Fujiwara, N., Sasako, T., Shibahara, J., Kado, A., Okushin, K., Fujinaga, H., Tsutsumi, T., Nakagomi, R., et al. (2018) · Journal of Gastroenterology · doi:10.1007/s00535-018-1472-0 · Cited by 35
The Mexican consensus on nonalcoholic fatty liver disease
Bernal-Reyes, R., Castro‐Narro, G., Malé-Velázquez, R., Carmona-Sánchez, R., González-Huezo, M. S., García-Juárez, I., Chávez-Tapia, N. C., Aguilar-Salinas, C., Aiza-Haddad, I., Ballesteros-Amozurrutia, M. A., et al. (2019) · Revista de Gastroenterología de México (English Edition) · doi:10.1016/j.rgmxen.2019.02.003 · Cited by 47
Yan, M., Man, S., Ma, L., & Gao, W. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155264 · Cited by 35
Non-alcoholic fatty liver disease: Immunological mechanisms and current treatments
Petagine, L., Zariwala, M. G., & Patel, V. B. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i32.4831 · Cited by 45
Caldwell, S. H., Patrie, J. T., Brunt, E. M., Redick, J. A., Davis, C. A., Park, S. H., & Neuschwander‐Tetri, B. A. (2007) · Hepatology · doi:10.1002/hep.21813 · Cited by 34
DeFronzo, R. A., Mehta, R. J., & Schnure, J. J. (2013) · Hospital Practice · doi:10.3810/hp.2013.04.1062 · Cited by 39
Self-citationKajikawa, S., Harada, T., Kawashima, A., Imada, K., & Mizuguchi, K. (2009) · Digestive Diseases and Sciences · doi:10.1007/s10620-009-1020-0 · Cited by 39
“Recently, several clinical trials using insulin-sensitizing medications have been shown to improve hepatic steatosis and insulin sensitivity in NASH patients [4, 5].”
Pharmacotherapy for Nonalcoholic Fatty Liver Disease
Gawrieh, S., & Chalasani, N. (2015) · Seminars in Liver Disease · doi:10.1055/s-0035-1562951 · Cited by 34
Pioglitazone reduces epicardial fat and improves diastolic function in patients with type 2 diabetes
Moody, A. J., Molina‐Wilkins, M., Clarke, G. D., Merovci, A., Solis‐Herrera, C., Cersósimo, E., CHILTON, R. J., Iozzo, P., Gastaldelli, A., Abdul‐Ghani, M. A., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14885 · Cited by 41
“In adipocytes, pioglitazone inhibits lipolysis, leading to a marked reduction in plasma free fatty acid (FFA) concentration,(24) and redistributes fat from muscle, liver, and visceral fat depots to subcutaneous fat depots.(18,25-29) In the heart we have shown that pioglitazone improves LV ejection fraction and multipl…”
BackgroundSelf-citationPioglitazone on nonalcoholic steatohepatitis: A systematic review and meta-analysis of 15 RCTs
Zhao, Y. D., Zhao, W., Wang, H., Zhao, Y., Bu, H., & Takahashi, H. (2022) · Medicine · doi:10.1097/md.0000000000031508 · Cited by 35
Treatment of non‐alcoholic steatohepatitis with Phyllanthus urinaria: A randomized trial
Wong, V. W., Wong, G. L., Chan, A. W., Chu, W. C., Choi, P. C., Chim, A. M., Yiu, K. K., Yu, J., Chan, F. K., & Chan, H. L. (2013) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2012.07286.x · Cited by 34
TINIAKOS, D. G., Anstee, Q. M., & Burt, A. D. (2017) · Elsevier eBooks · doi:10.1016/b978-0-7020-6697-9.00005-4 · Cited by 37
Xiao, F., Waldrop, S. L., Bronk, S. F., Gores, G. J., Davis, L. S., & Kilic, G. (2015) · Purinergic Signalling · doi:10.1007/s11302-015-9456-5 · Cited by 38
“Nonalcoholic steatohepatitis (NASH) has emerged as the most common cause of chronic liver injury in developed countries [1].”
BackgroundInfluentialCost effectiveness of duloxetine in the treatment of diabetic peripheral neuropathic pain in the UK
Beard, S. M., McCrink, L., Le, T. K., Garcia-Cebrian, A., Monz, B. U., & Malik, R. A. (2007) · Current Medical Research and Opinion · doi:10.1185/030079908x253852 · Cited by 34
Kurosaki, M., Matsunaga, K., Hirayama, I., Tanaka, T., Sato, M., Komatsu, N., Umeda, N., Hosokawa, T., Ueda, K., Tsuchiya, K., et al. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2007.12.025 · Cited by 34
“A recent study showed that the administration of pioglitazone led to metabolic and histological improvement in subjects with non-alcoholic steatohepatitis [24].”
BackgroundHepatitis C Infection and Nonalcoholic Fatty Liver Disease
Cheung, O., & Sanyal, A. J. (2008) · Clinics in Liver Disease · doi:10.1016/j.cld.2008.03.005 · Cited by 38
The role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail? A narrative review
Zachou, M., Flevari, P., Ansari, N. N., Varytimiadis, C., Kalaitzakis, E., Kassi, E. N., & Ανδρουτσάκος, Θ. (2023) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-023-03586-1 · Cited by 42
Therapeutic regulation of apoB100 metabolism in insulin resistance in vivo
Watts, G. F., Ooi, E. M. M., & Chan, D. C. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.04.005 · Cited by 35
“Other studies have demonstrated that pioglitazone treatment reduces liver fat content in subjects with impaired glucose tolerance or type 2 diabetes (Bajaj et al., 2003; Belfort et al., 2006).”
Backgroundvan Werven, J. R., Schreuder, T. C. M. A., Nederveen, A. J., Lavini, C., Jansen, P. L. M., & Stoker, J. (2010) · European Journal of Radiology · doi:10.1016/j.ejrad.2009.12.033 · Cited by 36
Risk of Obesity-Related Cardiometabolic Complications in Special Populations: A Crisis in Asians
Abate, N. I., & Chandalia, M. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.01.046 · Cited by 41
The association of non-alcoholic fatty liver disease and atrial fibrillation: a review
Käräjämäki, A. J., Hukkanen, J., & Ukkola, O. H. (2018) · Annals of Medicine · doi:10.1080/07853890.2018.1492147 · Cited by 37
Huang, M.-Y., Chung, C., Chang, W., Lin, C., Chen, K., Hsieh, T., Chien, W., & Lin, H. (2017) · PubMed · Cited by 35
The Impact of Nonalcoholic Fatty Liver Disease in Primary Care: A Population Health Perspective
Dokmak, A., Lizaola‐Mayo, B., & Trivedi, H. D. (2020) · The American Journal of Medicine · doi:10.1016/j.amjmed.2020.08.010 · Cited by 35
Song, T., Jia, Y., Li, Z., Wang, F., Ren, L., & Chen, S. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01072-4 · Cited by 37
Marchesini, G., Bugianesi, E., Burra, P., Marra, F., Miele, L., Alisi, A., Vajro, P., Masarone, M., Petta, S., Persico, M., et al. (2021) · Digestive and Liver Disease · doi:10.1016/j.dld.2021.04.029 · Cited by 38
Hepatic Effects of Rosiglitazone in Rats with the Metabolic Syndrome
Ackerman, Z., Oron‐Herman, M., Pappo, O., Peleg, E., Safadi, R., Schmilovitz‐Weiss, H., & Grozovski, M. (2010) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2010.00553.x · Cited by 34
Lebovics, E., & Rubin, J. N. (2011) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1198 · Cited by 37
“In a 6-month study of patients with T2DM or impaired glucose tolerance, pioglitazone decreased ALT, decreased hepatic fat content, increased hepatic insulin sensitivity, and improved steatosis, ballooning necrosis, and necroinflammation, but reduction in fibrosis did not differ significantly from that in the placebo g…”
BackgroundNonalcoholic fatty liver disease and cardiovascular disease risk
Schindhelm, R. K., Diamant, M., & Heine, R. J. (2007) · Current Diabetes Reports · doi:10.1007/s11892-007-0030-6 · Cited by 36
Empagliflozin Reduces Liver Fat in Individuals With and Without Diabetes
Abdelgani, S., Khattab, A., Adams, J. M., Baskoy, G., Brown, M., Clarke, G., Larvenenko, O., DeFronzo, R. A., & Abdul‐Ghani, M. A. (2024) · Diabetes Care · doi:10.2337/dc23-1646 · Cited by 44
Self-citationEnvironmental and Genetic Determinants of Fatty Liver in Humans
Kantartzis, K., Schick, F., Häring, H., & Stefan, N. (2010) · Digestive Diseases · doi:10.1159/000282082 · Cited by 32
“in humans. Furthermore, treatment of type 2 diabetic patients with thiazolidinediones, which increase circulating adiponectin, results in a decrease in liver fat content [”
BackgroundInvestigational anti-hyperglycemic agents: the future of type 2 diabetes therapy?
Majumdar, S. K., & Inzucchi, S. E. (2013) · Endocrine · doi:10.1007/s12020-013-9884-3 · Cited by 41
Zhang, W., Wu, R., Zhang, F., Xu, Y.-Z., Liu, B., Yang, Y., Zhou, H., Wang, L., Wan, K., Xiao, X., et al. (2012) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12020 · Cited by 34
“The findings of the present study confirm the results of previous studies reporting that TZDs treatment lowers circulating FFA levels and diminishes hepatic fat deposition in humans with T2DM.24,25 In the present study, we found that serum adiponectin concentrations and hepatic adiponectin mRNA expression decreased si…”
BackgroundInfluentialThe Role of Medications for the Management of Patients with NAFLD
Mazzella, N., Ricciardi, L. M., Mazzotti, A., & Marchesini, G. (2013) · Clinics in Liver Disease · doi:10.1016/j.cld.2013.09.005 · Cited by 35
Nonalcoholic Steatohepatitis and Endpoints in Clinical Trials.
Hannah, W. N., Torres, D. M., & Harrison, S. A. (2016) · PubMed Central · Cited by 39
Self-citationNAFLD in type 2 diabetes mellitus: Still many challenging questions
Cernea, S., & Raz, I. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3386 · Cited by 39
“histologic improvement (except fibrosis) with pioglitazone treatment (Table 3).(129) However, there is no proof so far that therapy with pioglitazone beyond 18 months brings additional histological benefits,”
BackgroundClinical implications, diagnosis, and management of diabetes in patients with chronic liver diseases
Chung, W., Promrat, K., & Wands, J. R. (2020) · World Journal of Hepatology · doi:10.4254/wjh.v12.i9.533 · Cited by 36
Jia, Y., Wu, C., Rivera‐Piza, A., Kim, Y., Lee, J. H., & Lee, S. (2022) · Antioxidants · doi:10.3390/antiox11040749 · Cited by 38
“Plasma adiponectin levels decrease sharply in obese patients with fatty liver disease [46].”
BackgroundTao, G., Zhang, G., Chen, W., Yang, C., Xue, Y., Song, G., & Qin, S. (2022) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17456 · Cited by 37
López, Y. O. N., Casu, A., Kováčová, Z., Petrilli, A. M., Sideleva, O., Tharp, W. G., & Pratley, R. E. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.955593 · Cited by 34
“Free fatty acids (FFA) were measured using the HR Series NEFA-HR (2) (Wako, Mountain View, CA) following the manufacturer’s instructions.”
MethodPromising hepatoprotective effects of lycopene in different liver diseases
Ibrahim, I. M., Althagafy, H. S., Abd‐alhameed, E. K., Al-Thubiani, W. S., & Hassanein, E. H. M. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.121131 · Cited by 37
Beuers, U. H., Kullak-Ublick, G. A., Pusl, T., Rauws, E. A., & Rust, C. (2008) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-008-8085-y · Cited by 33
Treatment of NASH with ursodeoxycholic acid: Pro
Ratziu, V. (2012) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/s2210-7401(12)70020-7 · Cited by 34
Non-alcoholic Steatohepatitis: An Overview
Shifflet, A., & Wu, G. Y. (2009) · Journal of the Formosan Medical Association · doi:10.1016/s0929-6646(09)60026-7 · Cited by 32
Insulin resistance is associated with liver stiffness in HIV/HCV co-infected patients
Merchante, N., Rivero, A., Santos, I. D. L., Merino, D., Márquez, M., López‐Ruz, M. Á., Rodríguez‐Baño, J., del Valle, J., Camacho, Á., Sanz-Sanz, J., et al. (2009) · Gut · doi:10.1136/gut.2009.179085 · Cited by 38
“In summary, this study demonstrates that IR is associated with LS in patients co-infected with HIV/HCV. Besides, our results suggest that IR may be mainly caused by classical metabolic factors or ART rather than HCV viral factors and may promote liver disease progression, probably inducing NASH, in patients infected w…”
ResultLeikin-Frenkel, A. I., Goldiner, I., Leikin-Gobbi, D., Rosenberg, R. A., Bonen, H., Litvak, A., Bernheim, J., Konikoff, F. M., & Gilat, T. (2008) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e3282fc9743 · Cited by 33
The challenge of managing dyslipidemia in patients with nonalcoholic fatty liver disease
Bril, F., Lomonaco, R., & Cusi, K. (2012) · Clinical Lipidology · doi:10.2217/clp.12.47 · Cited by 32
Self-citationGFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes
Cariou, B., & Staels, B. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.954034 · Cited by 36
Davies, M. J., Lim, S. K., Slater, T., Goldney, J., Philis‐Tsimikas, A., Franco, D. R., Lamptey, R., Yates, T. E., Tankova, T. I., & Lingvay, I. (2026) · Nature Reviews Disease Primers · doi:10.1038/s41572-026-00687-w · Cited by 64
Management of fatty liver disease with the metabolic syndrome
Machado, M. V., & Cortez‐Pinto, H. (2014) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2014.903798 · Cited by 33
“Three randomized trials with pioglitazone [112,120,121], including the PIVENS, besides the obvious benefit in glucose control, showed improvement in steatosis and inflammation, but only one in fibrosis [121].”
BackgroundCurative effect of arjunolic acid from Terminalia arjuna in non-alcoholic fatty liver disease models
Toppo, E., Darvin, S. S., Esakkimuthu, S., Buvanesvaragurunathan, K., Krishna, T. P. A., Caesar, S. A., Stalin, A., Balakrishna, K., Pandikumar, P., Savarimuthu Ignacimuthu, S. J., et al. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.08.019 · Cited by 37
Therapy for Nonalcoholic Fatty Liver Disease: Current Options and Future Directions
Campbell, P. T., Symonds, A., & Barritt, A. S. (2021) · Clinical Therapeutics · doi:10.1016/j.clinthera.2021.01.021 · Cited by 34
Shakour, N., Sahebkar, A., Karimi, G., Paseban, M., Tasbandi, A., Mosaffa, F., Tayarani‐Najaran, Z., Ghodsi, R., & Hadizadeh, F. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105162 · Cited by 32
ALY688 elicits adiponectin-mimetic signaling and improves insulin action in skeletal muscle cells
Sung, H. K., Mitchell, P. L., Gross, S. M., Marette, A., & Sweeney, G. (2021) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00603.2020 · Cited by 32
Muthiah, M. D., Ng, C. H., Xiao, J., Chin, Y. H., Lim, G., Lim, W. H., Tay, P. W. L., Tan, D. J. H., Yong, J. N., Pan, X., et al. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16808 · Cited by 32
Treating nonalcoholic fatty liver disease
Méndez‐Sánchez, N., Arrese, M. A., Zamora‐Valdés, D., & Uribe, M. (2007) · Liver International · doi:10.1111/j.1478-3231.2007.01567.x · Cited by 34
“(53) Randomizedcontrolled trial (n = 55) Pioglitazone and diet vs.”
BackgroundPharmacologic Therapy of Non-Alcoholic Steatohepatitis
Ratziu, V., & Zelber‐Sagi, S. (2009) · Clinics in Liver Disease · doi:10.1016/j.cld.2009.07.001 · Cited by 35
Davidson, M. B., & Pan, D. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.11.002 · Cited by 38
Authors, & Collaborators: (2022) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1880-2388 · Cited by 30
Congenital Lipodystrophies and Dyslipidemias
Prieur, X., May, C. L., Magré, J., & Cariou, B. (2014) · Current Atherosclerosis Reports · doi:10.1007/s11883-014-0437-x · Cited by 36
Treatment of Nonalcoholic Steatohepatitis in Adults: Present and Future
Gitto, S., Vitale, G., Villa, E., & Andreoné, P. (2015) · Gastroenterology Research and Practice · doi:10.1155/2015/732870 · Cited by 30
Siddiqui, M. S., & Charlton, M. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.077 · Cited by 31
Takashima, S., Ikejima, K., Arai, K., Yokokawa, J., Kon, K., Yamashina, S., & Watanabe, S. (2016) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00465.2015 · Cited by 30
“Among a variety of options, insulin sensitizers, such as thiazolidinedione derivatives, are the most commonly used drugs for treatment of NASH; however, the efficacy of thiazolidinedione derivatives in NASH patients remains controversial (5, 6, 33).”
BackgroundDrug Development for Nonalcoholic Fatty Liver Disease: Landscape and Challenges
Thiagarajan, P., & Aithal, G. P. (2019) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2019.03.002 · Cited by 33
Emerging therapies for the treatment of nonalcoholic steatohepatitis: A systematic review
Guirguis, E. H., Grace, Y., Bolson, A., DellaVecchia, M. J., & Ruble, M. J. (2021) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2489 · Cited by 35
Effects and Potential Mechanisms of Pioglitazone on Lipid Metabolism in Obese Diabetic KKAy Mice
Peng, J., Huan, Y., Jiang, Q., Sun, S., Jia, C., & Shen, Z. (2014) · PPAR Research · doi:10.1155/2014/538183 · Cited by 32
Cassiman, D. M., & Jaeken, J. (2008) · Gut · doi:10.1136/gut.2007.123240 · Cited by 30
McCarty, M. F. (2011) · Medical Hypotheses · doi:10.1016/j.mehy.2011.06.029 · Cited by 35
Current Therapeutical Approaches Targeting Lipid Metabolism in NAFLD
Vitulo, M., Gnodi, E., Rosini, G., Meneveri, R., Giovannoni, R., & Barisani, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612748 · Cited by 37
“An initial study detected a reduction in liver enzymes in NASH patients, with an improvement in histological parameters and a reduction in liver lipids and plasma triglycerides [195,196], and subsequent trials confirmed these data in NAFLD and type 2 diabetes patients [197,198] and in NASH subjects [199].”
BackgroundResultClinicopathological features of non‐alcoholic fatty liver disease
Sugimoto, K., & Takei, Y. (2011) · Hepatology Research · doi:10.1111/j.1872-034x.2011.00867.x · Cited by 33
A pilot trial of high-dose ursodeoxycholic acid in nonalcoholic steatohepatitis
Adams, L. A., Angulo, P., Petz, J., Keach, J. C., & Lindor, K. D. (2010) · Hepatology International · doi:10.1007/s12072-010-9195-1 · Cited by 31
“These have shown promise in improving liver histology in patients with nonalcoholic steatohepatitis (NASH), however, they are relatively expensive and have side effects of weight gain [ 4 ], and possibly increased cardiovascular risk [5].”
BackgroundTang, A., Chen, J. R., Le, T., Changchien, C., Hamilton, G., Middleton, M. S., Loomba, R. S., & Sirlin, C. B. (2014) · Abdominal Imaging · doi:10.1007/s00261-014-0175-0 · Cited by 30
Itou, M., Kawaguchi, T., Taniguchi, E., Oriishi, T., & Sata, M. (2012) · Case Reports in Gastroenterology · doi:10.1159/000341510 · Cited by 32
Lian, J., & Fu, J. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.649018 · Cited by 31
Metadata
- Authors
- Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., Berria, R., Ma, J. Z., Dwivedi, S., Havranek, R., Fincke, C., DeFronzo, R., Bannayan, G. A., Schenker, S., & Cusi, K.
- Affiliations
- The University of Texas at San Antonio Health Science Center (US)
- Brooke Army Medical Center (US)
- South Texas Veterans Health Care System (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-11-30
- Volume
- 355
- Issue
- 22
- Pages
- 2297-2307
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2103156933
- Cited by
- 1,827
- References
- 38
- Citations by year
- 2026: 44 · 2025: 73 · 2024: 83 · 2023: 78 · 2022: 84 · 2021: 93 · 2020: 73 · 2019: 74 · 2018: 70 · 2017: 93 · 2016: 98 · 2015: 106 · 2014: 92 · 2013: 87 · 2012: 85
- FWCI
- 91.90
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- INFM-OAR (INFN Catania) (submittedVersion, other-oa)
- Funders
- National Center for Research Resources (M01RR01346, M01RR001346)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- alcoholic steatohepatitis, thiazolidinediones, insulin resistance, hypocaloric diet, hepatic steatosis, hepatic insulin sensitivity, necroinflammation, liver fibrosis, glucose tolerance, type 2 diabetes, impaired glucose tolerance, hepatic aminotransferases, drug safety, adverse effects
- MeSH terms
- Pioglitazone, Blood Glucose, Combined Modality Therapy, Diabetes Mellitus, Type 2, Double-Blind Method, Fatty Liver, Female, Hepatitis, Humans, Hypoglycemic Agents, Insulin, Insulin Resistance, Liver, Liver Cirrhosis, Male, Middle Aged, Necrosis, Glucose Intolerance, Caloric Restriction, Thiazolidinediones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.